title: Color Doppler imaging of ocular blood flow after combined photodynamic therapy with intravitreal triamcinolone in age-related macular degeneration.
abstract: OBJECTIVE
  To investigate the effect of combined intravitreal triamcinolone and ocular photodynamic therapy on retinal and choroidal hemodynamics in age-related macular degeneration.
  
  
  METHODS
  Intravitreal triamcinolone (4 mg, 0.1 cc) and photodynamic therapy with verteporfin were applied to 48 eyes of 33 subjects (25 male and 8 female; mean age: 68.9 years) with subfoveal choroidal neovascular membrane secondary to age-related macular degeneration. Patients were assessed for ocular hemodynamic parameters with color Doppler imaging 24 hr before and 1 week, 1 month, and 3 months after a single-dose administration of combined intravitreal triamcinolone and photodynamic therapy.
  
  
  RESULTS
  Throughout the study period, no significant difference in resistance index, peak systolic velocity, or end diastolic velocity existed in the ophthalmic artery (P  =  0.58, P  =  0.18, and P  =  0.19, respectively), the posterior ciliary arteries (P  =  0.73, P  =  0.19, and P  =  0.34, respectively), or the central retinal artery (P  =  0.09, P  =  0.32, and P  =  0.47, respectively).
  
  
  CONCLUSIONS
  Combined intravitreal triamcinolone and photodynamic therapy was not associated with any alteration in ocular blood flow or flow velocity over 3 months in eyes with age-related macular degeneration.
authors.affiliation: Department of Ophthalmology, Vakıf Gureba Training and Research Hospital, Istanbul, Turkey. ocekic@hotmail.com
authors.forename: Osman
authors.initials: O
authors.lastname: Cekiç
authors.forename: Yavuz
authors.initials: Y
authors.lastname: Bardak
authors.forename: Ahmet
authors.initials: A
authors.lastname: Yeşildağ
mesh_terms: D000368:Aged; D000369:Aged, 80 and over; D001783:Blood Flow Velocity / Q000187:drug effects; D020256:Choroidal Neovascularization / Q000188:drug therapy / Q000503:physiopathology; D019842:Ciliary Arteries / Q000187:drug effects / Q000502:physiology; D003131:Combined Modality Therapy; D005260:Female; D005938:Glucocorticoids / Q000627:therapeutic use*; D006801:Humans; D058449:Intravitreal Injections; D008268:Macular Degeneration / Q000188:drug therapy* / Q000503:physiopathology*; D008297:Male; D008875:Middle Aged; D009880:Ophthalmic Artery / Q000187:drug effects / Q000502:physiology; D010778:Photochemotherapy; D017319:Photosensitizing Agents / Q000627:therapeutic use; D011166:Porphyrins / Q000627:therapeutic use; D012039:Regional Blood Flow / Q000187:drug effects; D012161:Retinal Artery / Q000187:drug effects / Q000502:physiology; D014222:Triamcinolone Acetonide / Q000627:therapeutic use*; D018615:Ultrasonography, Doppler, Color; D000077362:Verteporfin; D014792:Visual Acuity
chemical_list: D005938:Glucocorticoids; D017319:Photosensitizing Agents; D011166:Porphyrins; D000077362:Verteporfin; D014222:Triamcinolone Acetonide